[1] Black CJ, Ford AC.Global burden of irritable bowel syndrome: trends, predictions and risk factors[J]. Nat Rev Gastroenterol Hepatol,2020,17(8): 473-486.
[2] Oka P, Parr H, Barberio B, et al.Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol, 2020, 5(10): 908-917.
[3] Fagoonee S, Pellicano R.Does the Microbiota Play a Pivotal Role in the Pathogenesis of Irritable Bowel Syndrome?[J]. J Clin Med, 2019, 8(11): 1808.
[4] Mearin F, Lacy BE, Chang L, et al.Bowel Disorders[J]. Gastroenterology, 2016, 150: 1393-1407.
[5] Chao G, Wang Z, Zhang S.Research on Correlation Between Psychological Factors, Mast Cells, and PAR-2 Signal Pathway in Irritable Bowel syndrome[J]. J Inflamm Res, 2021, 14: 1427-1436.
[6] Creed F.Review article: the incidence and risk factors for irritable bowel syndrome in population-based studies[J]. Aliment Pharmacol Ther, 2019, 50(5): 507-516.
[7] Grad S, Dumitrascu DL.Irritable Bowel Syndrome Subtypes: New Names for Old Medical Conditions[J]. Dig Dis, 2020, 38(2): 122-127.
[8] Barbara G, Grover M, Bercik P, et al.Rome Foundation Working Team Report on Post-Infection Irritable Bowel Syndrome[J]. Gastroenterology, 2019, 156(1): 46-58.
[9] Mishima Y, Ishihara S.Molecular Mechanisms of Microbiota-Mediated Pathology in Irritable Bowel Syndrome[J]. Int J Mol Sci, 2020, 21(22): 8664.
[10] Ianiro G, Tilg H, Gasbarrini A.Antibiotics as deep modulators of gut microbiota: between good and evil[J]. Gut, 2016, 65(11): 1906-1915.
[11] Takakura W, Pimentel M.Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome-An Update[J]. Front Psychiatry, 2020, 11: 664.
[12] Wang L, Alammar N, Singh R, et al.Gut Microbial Dysbiosis in the Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Case-Control Studies[J]. J Acad Nutr Diet, 2020, 120(4): 565-586.
[13] Pittayanon R, Lau JT, Yuan Y, et al.Gut Microbiota in Patients With Irritable Bowel Syndrome-A Systematic Review[J]. Gastroenterology, 2019, 157(1): 97-108.
[14] Chong PP, Chin VK, Looi CY, et al.The Microbiome and Irritable Bowel Syndrome-A Review on the Pathophysiology, Current Research and Future Therapy [published correction appears in Front Microbiol[J]. Front Microbiol, 2019, 10: 1136.
[15] Raskov H, Burcharth J, Pommergaard HC, et al.Irritable bowel syndrome, the microbiota and the gut-brain axis[J]. Gut Microbes, 2016, 7(5): 365-383.
[16] Andrews CN, Sidani S, Marshall JK.Clinical Management of the Microbiome in Irritable Bowel Syndrome[J]. J Can Assoc Gastroenterol, 2020, 4(1): 36-43.
[17] Raskov H, Burcharth J, Pommergaard HC, et al.Irritable bowel syndrome, the microbiota and the gut-brain axis[J]. Gut Microbes, 2016, 7(5): 365-383.
[18] Distrutti E, Monaldi L, Ricci P, et al.Gut microbiota role in irritable bowel syndrome: New therapeutic strategies[J]. World J Gastroenterol, 2016, 22(7): 2219-2241.
[19] HIGHLIGHTS OF PRESCRIBING INFORMATION:Rifaximin
[20] [EB/OL].Maryland:Clinical Trials, 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021361s023lbl.pdf.
[21] Fodor AA, Pimentel M, Chey WD, et al.Rifaximin is associated with modest, transient decreases in multiple taxa in the gut microbiota of patients with diarrhoea-predominant irritable bowel syndrome[J]. Gut Microbes, 2019, 10(1): 22-33.
[22] Li B, Liang L, Deng H, et al.Efficacy and Safety of Probiotics in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis[J]. Front Pharmacol, 2020, 11: 332.
[23] Plaza-Diaz J, Ruiz-Ojeda FJ, Gil-Campos M, et al.Mechanisms of Action of Probiotics[J]. Adv Nutr, 2019, 10: S49-S66.
[24] Markowiak P, Śliżewska K.Effects of Probiotics, Prebiotics, and Synbiotics on Human Health[J]. Nutrients, 2017, 9(9): 1021.
[25] Dai YJ, Wang HY, Wang XJ, et al.Potential Beneficial Effects of Probiotics on Human Migraine Headache: A Literature Review[J]. Pain Physician, 2017, 20(2): E251-E255.
[26] Krammer H, Storr M, Madisch A, et al.Reizdarmbehandlung mit Lactobacillus plantarum 299v: Längere Einnahme verstärkt Behandlungserfolg-Ergebnisse einer nichtinterventionellen Studie[J]. Z Gastroenterol, 2021, 59(2): 125-134.
[27] Bahrudin MF, Abdul Rani R, Tamil AM, et al.Effectiveness of Sterilized Symbiotic Drink Containing Lactobacillus helveticus Comparable to Probiotic Alone in Patients with Constipation-Predominant Irritable Bowel Syndrome[J]. Dig Dis Sci, 2020, 65(2): 541-549.
[28] Wen Y, Li J, Long Q, et al.The efficacy and safety of probiotics for patients with constipation-predominant irritable bowel syndrome: A systematic review and meta-analysis based on seventeen randomized controlled trials[J]. Int J Surg, 2020, 79: 111-119.
[29] Hod K, Dekel R, Aviv Cohen N, et al.The effect of a multispecies probiotic on microbiota composition in a clinical trial of patients with diarrhea-predominant irritable bowel syndrome[J]. Neurogastroenterol Motil, 2018, 30(12): e13456.
[30] Sun YY, Li M, Li YY, et al.The effect of Clostridium butyricum on symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial[J]. Sci Rep, 2018, 8(1): 2964.
[31] Skrzydło-Radomańska B, Prozorow-Król B, Cichoż-Lach H, et al.The Effectiveness and Safety of Multi-Strain Probiotic Preparation in Patients with Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized Controlled Study[J]. Nutrients, 2021, 13(3): 756.
[32] Caviglia GP, Tucci A, Pellicano R, et al.Clinical Response and Changes of Cytokines and Zonulin Levels in Patients with Diarrhoea-Predominant Irritable Bowel Syndrome Treated with Bifidobacterium Longum ES1 for 8 or 12 Weeks: A Preliminary Report[J]. J Clin Med, 2020, 9(8): 2353.
[33] Mack I, Schwille-Kiuntke J, Mazurak N, et al.A Nonviable Probiotic in Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study[J]. Clin Gastroenterol Hepatol, 2022, 20(5): 1039-1047.
[34] Ford AC, Harris LA, Lacy BE, et al.Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome[J]. Aliment Pharmacol Ther, 2018, 48(10): 1044-1060.
[35] Niu HL, Xiao JY.The efficacy and safety of probiotics in patients with irritable bowel syndrome: Evidence based on 35 randomized controlled trials[J]. Int J Surg, 2020, 75: 116-127.
[36] Catinean A, Neag AM, Nita A, et al.Spores-A Promising Treatment Option for Patients with Irritable Bowel Syndrome[J]. Nutrients, 2019, 11(9): 1968.
[37] Preston K, Krumian R, Hattner J, et al.Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R and Lactobacillus rhamnosus CLR2 improve quality-of-life and IBS symptoms: a double-blind, randomised, placebo-controlled study[J]. Benef Microbes, 2018, 9(5): 697-706.
[38] Oh JH, Jang YS, Kang D, et al.Efficacy and Safety of New Lactobacilli Probiotics for Unconstipated Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial[J]. Nutrients, 2019, 11(12): 2887.
[39] Martoni CJ, Srivastava S, Leyer GJ.Lactobacillus acidophilus DDS-1 and Bifidobacterium lactis UABla-12 Improve Abdominal Pain Severity and Symptomology in Irritable Bowel Syndrome: Randomized Controlled Trial[J]. Nutrients, 2020, 12(2): 363.
[40] Madempudi RS, Ahire JJ, Neelamraju J, et al.Randomized clinical trial: the effect of probiotic Bacillus coagulans Unique IS2 vs. placebo on the symptoms management of irritable bowel syndrome in adults[J]. Sci Rep, 2019, 9(1): 12210.
[41] Gupta AK, Maity C.Efficacy and safety of Bacillus coagulans LBSC in irritable bowel syndrome: A prospective, interventional, randomized, double-blind, placebo-controlled clinical study[J]. Medicine (Baltimore), 2021, 100(3): e23641.
[42] Andresen V, Gschossmann J, Layer P.Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001) in the treatment of irritable bowel syndrome: a multicentre, randomised, double-blind, placebo-controlled clinical trial[J]. Lancet Gastroenterol Hepatol, 2020, 5(7): 658-666.
[43] Sudha MR, Jayanthi N, Aasin M, et al.Efficacy of Bacillus coagulans Unique IS2 in treatment of irritable bowel syndrome in children: a double blind, randomised placebo controlled study[J]. Benef Microbes, 2018, 9(4): 563-572.
[44] Rahmani P, Ghouran-Orimi A, Motamed F, et al.Evaluating the effects of probiotics in pediatrics with recurrent abdominal pain[J]. Clin Exp Pediatr, 2020, 63(12): 485-490.
[45] Xu HL, Zou LL, Chen MB, et al.Efficacy of probiotic adjuvant therapy for irritable bowel syndrome in children: A systematic review and meta-analysis[J]. PLoS One, 2021, 16(8): e0255160.
[46] Zamani M, Alizadeh-Tabari S, Zamani V.Systematic review with meta-analysis: the prevalence of anxiety and depression in patients with irritable bowel syndrome[J]. Aliment Pharmacol Ther, 2019, 50(2): 132-143.
[47] Barbara G, Feinle-Bisset C, Ghoshal UC, et al.The Intestinal Microenvironment and Functional Gastrointestinal Disorders[J]. Gastroenterology, 2016, 150: 1305-1318.
[48] Drossman DA, Hasler WL.Rome IV-Functional GI disorders: Disorders of gut-brain interaction[J]. Gastroenterology, 2016, 150(6): 1257-1261.
[49] Skrzydło-Radomańska B, Prozorow-Król B, Cichoż-Lach H, et al.The Effectiveness and Safety of Multi-Strain Probiotic Preparation in Patients with Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized Controlled Study[J]. Nutrients, 2021, 13(3): 756.
[50] Xie Y, Zhou G, Xu Y, et al.Effects of Diet Based on IgG Elimination Combined with Probiotics on Migraine Plus Irritable Bowel Syndrome[J]. Pain Res Manag, 2019, 2019:7890461. doi: 10.1155/ 2019/7890461.
[51] Pinto-Sanchez MI, Hall GB, Ghajar K, et al.Probiotic Bifidobacterium longum NCC3001 reduces depression scores and alters brain activity: a pilot study in patients with irritable bowel syndrome[J]. Gastroenterology, 2017, 153(2): 448-459. |
